GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Scope Fluidics Spolka Akcyjna (WAR:SCP) » Definitions » Altman Z-Score

Scope Fluidics Spolka Akcyjna (WAR:SCP) Altman Z-Score : 15.46 (As of Mar. 26, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Scope Fluidics Spolka Akcyjna Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 15.45 is strong.

Scope Fluidics Spolka Akcyjna has a Altman Z-Score of 15.46, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's Altman Z-Score or its related term are showing as below:

WAR:SCP' s Altman Z-Score Range Over the Past 10 Years
Min: -2.53   Med: 15.8   Max: 32.85
Current: 15.45

During the past 8 years, Scope Fluidics Spolka Akcyjna's highest Altman Z-Score was 32.85. The lowest was -2.53. And the median was 15.80.


Scope Fluidics Spolka Akcyjna Altman Z-Score Historical Data

The historical data trend for Scope Fluidics Spolka Akcyjna's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scope Fluidics Spolka Akcyjna Altman Z-Score Chart

Scope Fluidics Spolka Akcyjna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial - - - 31.78 15.80

Scope Fluidics Spolka Akcyjna Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.25 15.80 15.89 13.34 13.68

Competitive Comparison of Scope Fluidics Spolka Akcyjna's Altman Z-Score

For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scope Fluidics Spolka Akcyjna's Altman Z-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Scope Fluidics Spolka Akcyjna's Altman Z-Score falls into.



Scope Fluidics Spolka Akcyjna Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Scope Fluidics Spolka Akcyjna's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.7688+1.4*-0.4337+3.3*-0.352+0.6*27.18+1.0*0.0015
=15.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was zł79.54 Mil.
Total Current Assets was zł67.10 Mil.
Total Current Liabilities was zł5.96 Mil.
Retained Earnings was zł-34.49 Mil.
Pre-Tax Income was -6.453 + -6.502 + -6.749 + -8.732 = zł-28.44 Mil.
Interest Expense was -0.292 + -0.001 + -0.214 + 0.07 = zł-0.44 Mil.
Revenue was 0.024 + 0.05 + 0.037 + 0.008 = zł0.12 Mil.
Market Cap (Today) was zł504.84 Mil.
Total Liabilities was zł18.57 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(67.103 - 5.96)/79.535
=0.7688

X2=Retained Earnings/Total Assets
=-34.494/79.535
=-0.4337

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-28.436 - -0.437)/79.535
=-0.352

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=504.842/18.574
=27.18

X5=Revenue/Total Assets
=0.119/79.535
=0.0015

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Scope Fluidics Spolka Akcyjna has a Altman Z-Score of 15.46 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Scope Fluidics Spolka Akcyjna  (WAR:SCP) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Scope Fluidics Spolka Akcyjna Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Scope Fluidics Spolka Akcyjna's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Scope Fluidics Spolka Akcyjna Business Description

Traded in Other Exchanges
Address
Duchnicka 3, Build 16, Entrance A, Warsaw, POL, 01-796
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.

Scope Fluidics Spolka Akcyjna Headlines

No Headlines